Cargando…
Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes
BACKGROUND: Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow‐up data from implanted devices to inve...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660760/ https://www.ncbi.nlm.nih.gov/pubmed/32814465 http://dx.doi.org/10.1161/JAHA.120.017086 |
_version_ | 1783609075357974528 |
---|---|
author | Weng, Willy Wiefels, Christiane Chakrabarti, Santabhanu Nery, Pablo B. Celiker-Guler, Emel Healey, Jeff S. Hruczkowski, Tomasz W. Quinn, F. Russell Promislow, Steven Medor, Maria C. Spence, Stewart Odabashian, Roupen Alqarawi, Wael Juneau, Daniel de Kemp, Rob Leung, Eugene Beanlands, Rob Birnie, David |
author_facet | Weng, Willy Wiefels, Christiane Chakrabarti, Santabhanu Nery, Pablo B. Celiker-Guler, Emel Healey, Jeff S. Hruczkowski, Tomasz W. Quinn, F. Russell Promislow, Steven Medor, Maria C. Spence, Stewart Odabashian, Roupen Alqarawi, Wael Juneau, Daniel de Kemp, Rob Leung, Eugene Beanlands, Rob Birnie, David |
author_sort | Weng, Willy |
collection | PubMed |
description | BACKGROUND: Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow‐up data from implanted devices to investigate AA incidence, burden, predictors, and response to immunosuppression. METHODS AND RESULTS: This project is a substudy of the CHASM‐CS (Cardiac Sarcoidosis Multicenter Prospective Cohort Study; NCT01477359). Inclusion criteria were presentation with clinically manifest cardiac sarcoidosis, treatment‐naive status, and implanted with a device that reported accurate AA burden. Data were collected at each device interrogation visit for all patients and all potential episodes of AA were adjudicated. For each intervisit period, the total AA burden was obtained. A total of 33 patients met the inclusion criteria (aged 56.1±7.7 years, 45.5% women). Only 1 patient had important AAs as a part of the initial CS presentation. During a median follow‐up of 49.1 months, 11 of 33 patients (33.3%) had device‐detected AAs, and only 2 (6.1%) had a clinically significant AA burden. Both patients had reduced burden after CS was successfully treated and there was no residual fluorodeoxyglucose uptake on positron emission tomography scan. CONCLUSIONS: First, we found that AAs are a rare presenting feature of clinically manifest cardiac sarcoidosis. Second, AAs occurred in a minority of patients at follow‐up; the burden was very low in most patients. Only 2 patients had clinically significant AA burden, and both had a reduction after CS was treated. REGISTRATION: URL: https://www.clinicaltrials.gov; unique identifier NCT01477359. |
format | Online Article Text |
id | pubmed-7660760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76607602020-11-17 Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes Weng, Willy Wiefels, Christiane Chakrabarti, Santabhanu Nery, Pablo B. Celiker-Guler, Emel Healey, Jeff S. Hruczkowski, Tomasz W. Quinn, F. Russell Promislow, Steven Medor, Maria C. Spence, Stewart Odabashian, Roupen Alqarawi, Wael Juneau, Daniel de Kemp, Rob Leung, Eugene Beanlands, Rob Birnie, David J Am Heart Assoc Original Research BACKGROUND: Recent data have suggested a substantial incidence of atrial arrhythmias (AAs) in cardiac sarcoidosis (CS). Our study aims were to first assess how often AAs are the presenting feature of previously undiagnosed CS. Second, we used prospective follow‐up data from implanted devices to investigate AA incidence, burden, predictors, and response to immunosuppression. METHODS AND RESULTS: This project is a substudy of the CHASM‐CS (Cardiac Sarcoidosis Multicenter Prospective Cohort Study; NCT01477359). Inclusion criteria were presentation with clinically manifest cardiac sarcoidosis, treatment‐naive status, and implanted with a device that reported accurate AA burden. Data were collected at each device interrogation visit for all patients and all potential episodes of AA were adjudicated. For each intervisit period, the total AA burden was obtained. A total of 33 patients met the inclusion criteria (aged 56.1±7.7 years, 45.5% women). Only 1 patient had important AAs as a part of the initial CS presentation. During a median follow‐up of 49.1 months, 11 of 33 patients (33.3%) had device‐detected AAs, and only 2 (6.1%) had a clinically significant AA burden. Both patients had reduced burden after CS was successfully treated and there was no residual fluorodeoxyglucose uptake on positron emission tomography scan. CONCLUSIONS: First, we found that AAs are a rare presenting feature of clinically manifest cardiac sarcoidosis. Second, AAs occurred in a minority of patients at follow‐up; the burden was very low in most patients. Only 2 patients had clinically significant AA burden, and both had a reduction after CS was treated. REGISTRATION: URL: https://www.clinicaltrials.gov; unique identifier NCT01477359. John Wiley and Sons Inc. 2020-08-20 /pmc/articles/PMC7660760/ /pubmed/32814465 http://dx.doi.org/10.1161/JAHA.120.017086 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Weng, Willy Wiefels, Christiane Chakrabarti, Santabhanu Nery, Pablo B. Celiker-Guler, Emel Healey, Jeff S. Hruczkowski, Tomasz W. Quinn, F. Russell Promislow, Steven Medor, Maria C. Spence, Stewart Odabashian, Roupen Alqarawi, Wael Juneau, Daniel de Kemp, Rob Leung, Eugene Beanlands, Rob Birnie, David Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
title | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
title_full | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
title_fullStr | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
title_full_unstemmed | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
title_short | Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes |
title_sort | atrial arrhythmias in clinically manifest cardiac sarcoidosis: incidence, burden, predictors, and outcomes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660760/ https://www.ncbi.nlm.nih.gov/pubmed/32814465 http://dx.doi.org/10.1161/JAHA.120.017086 |
work_keys_str_mv | AT wengwilly atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT wiefelschristiane atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT chakrabartisantabhanu atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT nerypablob atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT celikerguleremel atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT healeyjeffs atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT hruczkowskitomaszw atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT quinnfrussell atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT promislowsteven atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT medormariac atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT spencestewart atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT odabashianroupen atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT alqarawiwael atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT juneaudaniel atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT dekemprob atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT leungeugene atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT beanlandsrob atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes AT birniedavid atrialarrhythmiasinclinicallymanifestcardiacsarcoidosisincidenceburdenpredictorsandoutcomes |